Maria Valeria Corrias

List of Publications by Year
in descending order

90	2,824	172457 29	197818 49
papers	citations	h-index	g-index

90	90	90	3639
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Bilateral adrenal primary tumor in Stage 4S neuroblastoma: The Italian experience and review of the literature. Pediatric Hematology and Oncology, 2022, 39, 441-452.	0.8	1
2	Recent advances in the developmental origin of neuroblastoma: an overview. Journal of Experimental and Clinical Cancer Research, 2022, 41, 92.	8.6	46
3	Metastatic progression in infants diagnosed with stage 4S neuroblastoma. A study of the Italian Neuroblastoma Registry. Pediatric Blood and Cancer, 2021, 68, e28904.	1.5	3
4	Potential Role of miRNAs in the Acquisition of Chemoresistance in Neuroblastoma. Journal of Personalized Medicine, 2021, 11, 107.	2.5	7
5	Bone Marrow Environment in Metastatic Neuroblastoma. Cancers, 2021, 13, 2467.	3.7	5
6	Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy. Journal of Experimental and Clinical Cancer Research, 2021, 40, 180.	8.6	27
7	The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis. Nutrients, 2021, 13, 2178.	4.1	15
8	Retinoids Delivery Systems in Cancer: Liposomal Fenretinide for Neuroectodermal-Derived Tumors. Pharmaceuticals, 2021, 14, 854.	3.8	8
9	A Focus on Regulatory Networks Linking MicroRNAs, Transcription Factors and Target Genes in Neuroblastoma. Cancers, 2021, 13, 5528.	3.7	16
10	Neural crest-derived tumor neuroblastoma and melanoma share 1p13.2 as susceptibility locus that shows a long-range interaction with the SLC16A1 gene. Carcinogenesis, 2020, 41, 284-295.	2.8	18
11	Association of PARP1 polymorphisms with response to chemotherapy in patients with highâ€risk neuroblastoma. Journal of Cellular and Molecular Medicine, 2020, 24, 4072-4081.	3.6	12
12	Combined Replenishment of miRâ€34a and letâ€7b by Targeted Nanoparticles Inhibits Tumor Growth in Neuroblastoma Preclinical Models. Small, 2020, 16, e1906426.	10.0	27
13	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
14	Microvesicles expressing adenosinergic ectoenzymes and their potential role in modulating bone marrow infiltration by neuroblastoma cells. OncoImmunology, 2019, 8, e1574198.	4.6	29
15	HIF-1 transcription activity: HIF1A driven response in normoxia and in hypoxia. BMC Medical Genetics, 2019, 20, 37.	2.1	57
16	Plasma free metanephrines for diagnosis of neuroblastoma patients. Clinical Biochemistry, 2019, 66, 57-62.	1.9	14
17	Eventâ€free survival of infants and toddlers enrolled in the HRâ€NBLâ€1/SIOPEN trial is associated with the level of neuroblastoma mRNAs at diagnosis. Pediatric Blood and Cancer, 2018, 65, e27052.	1.5	7
18	Updated clinical and biological information from the two-stage phase II study of imatinib mesylate in subjects with relapsed/refractory neuroblastoma. OncoImmunology, 2018, 7, e1468953.	4.6	9

#	Article	IF	Citations
19	miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children. Oncotarget, 2018, 9, 19014-19025.	1.8	2
20	Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma. Scientific Reports, 2017, 7, 14049.	3.3	37
21	Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. Journal of Immunology, 2017, 199, 1516-1525.	0.8	41
22	Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma. Oncotarget, 2017, 8, 53194-53209.	1.8	13
23	Soluble HLA-G and HLA-E Levels in Bone Marrow Plasma Samples Are Related to Disease Stage in Neuroblastoma Patients. Journal of Immunology Research, 2016, 2016, 1-6.	2.2	10
24	Restricted ROC curves are useful tools to evaluate the performance of tumour markers. Statistical Methods in Medical Research, 2016, 25, 294-314.	1.5	7
25	CD4⁺CD25^{hi}CD127^{â˜’} Treg and CD4⁺CD45RO⁺CD49b⁺LAG3⁺ Tr1 cells in bone marrow and peripheral blood samples from children with neuroblastoma. OncoImmunology, 2016, 5, e1249553.	4.6	17
26	PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance. OncoImmunology, 2016, 5, e1064578.	4.6	91
27	Expression ofFOXP3,CD14, andARG1in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival. BioMed Research International, 2015, 2015, 1-10.	1.9	6
28	IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome. Journal of Immunology Research, 2015, 2015, 1-9.	2.2	16
29	Evaluation of bone marrow as a metastatic site of human neuroblastoma. Annals of the New York Academy of Sciences, 2015, 1335, 23-31.	3.8	25
30	NewÂimmunotherapeutic strategies for the treatment of neuroblastoma. Immunotherapy, 2015, 7, 285-300.	2.0	8
31	The interleukin (IL)-31/IL-31R axis contributes to tumor growth in human follicular lymphoma. Leukemia, 2015, 29, 958-967.	7.2	31
32	Deregulation of focal adhesion pathway mediated by miR-659-3p is implicated in bone marrow infiltration of stage M neuroblastoma patients. Oncotarget, 2015, 6, 13295-13308.	1.8	13
33	Neuroblastoma mRNAs Predict Outcome in Children With Stage 4 Neuroblastoma: A European HR-NBL1/SIOPEN Study. Journal of Clinical Oncology, 2014, 32, 1074-1083.	1.6	97
34	Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity. Cancer Immunology, Immunotherapy, 2014, 63, 501-511.	4.2	21
35	Seasonal variations of date of diagnosis and birth for neuroblastoma patients in Italy. Cancer Epidemiology, 2013, 37, 575-578.	1.9	5
36	Plasma Levels of Soluble HLA-E and HLA-F at Diagnosis May Predict Overall Survival of Neuroblastoma Patients. BioMed Research International, 2013, 2013, 1-9.	1.9	30

#	Article	IF	Citations
37	Two-stage phase II study of imatinib mesylate in subjects with refractory or relapsing neuroblastoma. Annals of Oncology, 2013, 24, 1406-1413.	1.2	13
38	Neuroblastoma-Derived TGF-Î²1 Modulates the Chemokine Receptor Repertoire of Human Resting NK Cells. Journal of Immunology, 2013, 190, 5321-5328.	0.8	128
39	Prognostic value of ferritin, neuron-specific enolase, lactate dehydrogenase, and urinary and plasmatic catecholamine metabolites in children with neuroblastoma. OncoTargets and Therapy, 2012, 5, 417.	2.0	27
40	Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatric Blood and Cancer, 2012, 58, 43-49.	1.5	25
41	Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature. Pediatric Blood and Cancer, 2012, 59, 44-51.	1.5	22
42	Identification of reference microRNAs and suitability of archived hemopoietic samples for robust microRNA expression profiling. Analytical Biochemistry, 2012, 421, 566-572.	2.4	32
43	Bone Marrow-Infiltrating Human Neuroblastoma Cells Express High Levels of Calprotectin and HLA-G Proteins. PLoS ONE, 2012, 7, e29922.	2.5	40
44	Role of Bone Marrow Infiltration Detected by Sensitive Methods in Patients with Localized Neuroblastoma. Pediatric Cancer, 2012, , 237-245.	0.0	0
45	Neuroblastoma: Perspectives for the Use of IL-21 in Immunotherapy. Pediatric Cancer, 2012, , 125-135.	0.0	0
46	Neuroblastoma and bone metastases: Clinical significance and prognostic value of Dickkopf 1 plasma levels. Bone, 2011, 48, 152-159.	2.9	26
47	Serum levels of cytoplasmic melanoma-associated antigen at diagnosis may predict clinical relapse in neuroblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 1485-1495.	4.2	21
48	Why Do Cancer Omics Attract Clinicians So Much?. OMICS A Journal of Integrative Biology, 2011, 15, 123-124.	2.0	2
49	Transient depletion of CD4⁺ T cells augments ILâ€21â€based immunotherapy of disseminated neuroblastoma in syngeneic mice. International Journal of Cancer, 2010, 127, 1141-1150.	5.1	24
50	Detection of cellâ€free RNA in children with neuroblastoma and comparison with that of whole blood cell RNA. Pediatric Blood and Cancer, 2010, 54, 897-903.	1.5	5
51	Different Subcellular Localization of ALCAM Molecules in Neuroblastoma: Association with Relapse. Analytical Cellular Pathology, 2010, 32, 77-86.	1.4	0
52	Different subcellular localization of ALCAM molecules in neuroblastoma: Association with relapse. Cellular Oncology, 2010, 32, 77-86.	1.9	7
53	Chemokines in neuroectodermal tumour progression and metastasis. Seminars in Cancer Biology, 2009, 19, 97-102.	9.6	26
54	Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen. Cancer Immunology, Immunotherapy, 2008, 57, 1625-1634.	4.2	35

#	Article	IF	Citations
55	Minimal disease monitoring by QRTâ€“PCR: guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. Journal of Pathology, 2008, 216, 245-252.	4.5	46
56	Detection of GD2-positive cells in bone marrow samples and survival of patients with localised neuroblastoma. British Journal of Cancer, 2008, 98, 263-269.	6.4	19
57	Small round blue cell tumours: diagnostic and prognostic usefulness of the expression of B7â€H3 surface molecule. Histopathology, 2008, 53, 73-80.	2.9	79
58	Umbilical Cord Blood Transplantation: Should Perinatal Solid Cancer Become a Matter of Concern?. Journal of the National Cancer Institute, 2008, 100, 1822-1823.	6.3	2
59	Tumor Origin of Endothelial Cells in Human Neuroblastoma. Journal of Clinical Oncology, 2007, 25, 376-383.	1.6	131
60	Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET. European Journal of Cancer, 2007, 43, 341-350.	2.8	59
61	Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunology, Immunotherapy, 2007, 56, 1733-1742.	4.2	44
62	Diagnostic identification of malignant cells in the cerebrospinal fluid by tumor-specific qRT-PCR. Clinical and Experimental Metastasis, 2006, 23, 223-226.	3.3	4
63	Comparison of different techniques and markers in the detection of neuroblastoma cells in bone marrow and peripheral blood samples: are they really equivalent?. Targeted Oncology, 2006, 1, 97-99.	3.6	0
64	CXCL12 Does Not Attract CXCR4+ Human Metastatic Neuroblastoma Cells: Clinical Implications. Clinical Cancer Research, 2006, 12, 77-82.	7.0	47
65	Peripheral Blood Stem Cell Tumor Cell Contamination and Survival of Neuroblastoma Patients. Clinical Cancer Research, 2006, 12, 5680-5685.	7.0	32
66	Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-Î³. British Journal of Cancer, 2006, 94, 1845-1852.	6.4	42
67	Effect of Bortezomib on Human Neuroblastoma Cell Growth, Apoptosis, and Angiogenesis. Journal of the National Cancer Institute, 2006, 98, 1142-1157.	6.3	125
68	Sequential immunogene therapy with interleukin-12- and interleukin-15-engineered neuroblastoma cells cures metastatic disease in syngeneic mice. Clinical Cancer Research, 2005, 11, 735-42.	7.0	21
69	Detection of Neuroblastoma Cells in Bone Marrow and Peripheral Blood by Different Techniques. Clinical Cancer Research, 2004, 10, 7978-7985.	7.0	37
70	Natural Killer Cell-Mediated Killing of Freshly Isolated Neuroblastoma Cells. Cancer Research, 2004, 64, 9180-9184.	0.9	224
71	Low-dose interferon-Î³-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity. British Journal of Cancer, 2004, 90, 2210-2218.	6.4	15
72	Immunogenicity of Human Neuroblastoma. Annals of the New York Academy of Sciences, 2004, 1028, 69-80.	3.8	48

#	Article	IF	Citations
73	Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 12640-12645.	7.1	248
74	Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression. Cancer Immunology, Immunotherapy, 2003, 52, 116-120.	4.2	9
75	Different levels of control prevent interferon-Î³-inducible HLA-class II expression in human neuroblastoma cells. Oncogene, 2003, 22, 7848-7857.	5.9	26
76	Recombinant antibodies in the immunotherapy of neuroblastoma: perspectives of new developments. Cancer Letters, 2003, 197, 193-198.	7.2	8
77	Expression of costimulatory molecules in human neuroblastoma. Evidence that CD40+ neuroblastoma cells undergo apoptosis following interaction with CD40L. British Journal of Cancer, 2003, 88, 1527-1536.	6.4	31
78	A novel syngeneic murine model for thoracic neuroblastoma obtained by intramediastinal injection of tumor cells. Cancer Detection and Prevention, 2002, 26, 468-475.	2.1	5
79	Lack of HLAâ€class I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens, 2001, 57, 110-117.	1.0	61
80	Full Cytogenetic Characterization of a New Neuroblastoma Cell Line with a Complex 17q Translocation. Cancer Genetics and Cytogenetics, 2000, 116, 124-132.	1.0	13
81	Bioavailability of antisense oligonucleotides in neuroblastoma cells: comparison of efficacy among different types of molecules. Journal of Neuro-Oncology, 1997, 31, 171-180.	2.9	6
82	Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. , 1996, 69, 403-407.		49
83	Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblastoma. , 1996, 69, 403.		1
84	Induction of 2,5 oas gene expression and activity is not sufficient for IFN-Î³-induced neuroblastoma cell differentiation. International Journal of Cancer, 1995, 62, 223-229.	5.1	10
85	Synergistic Differentiation-Promoting Activity of Interferon Â and Tumor Necrosis Factor-Â: Role of Receptor Regulation on Human Neuroblasts. Journal of the National Cancer Institute, 1994, 86, 1694-1701.	6.3	23
86	Cloning and sequencing of isoform-specific regions of human Ca2+ -independent protein kinase C (PKC)-encoding genes. Gene, 1994, 141, 307-308.	2.2	2
87	Uncoordinate induction and differential regulation of hla class-I and class-II expression by Î³-interferon in differentiating human neuroblastoma cells. International Journal of Cancer, 1993, 55, 817-823.	5.1	35
88	Protein kinase C isoenzymes in human neuroblasts involvement of PKCÎµ in cell differentiation. FEBS Letters, 1993, 322, 120-124.	2.8	37
89	A new peptide analog (RM06) modulates the growth of hematopoietic cells. International Journal of Immunopharmacology, 1991, 13, 1005-1012.	1.1	1
90	Expression of a gene for mouse eucaryotic elongation factor Tu during murine erythroleukemic cell differentiation.. Molecular and Cellular Biology, 1987, 7, 3929-3936.	2.3	37